Robak, Tadeusz <br/><br/>
Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.  [electronic resource] 

 -  The Lancet. Oncology  11 2018 
 - 1449-1458 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1474-5488 
<br/><br/><label>Standard No.: </label>10.1016/S1470-2045(18)30685-5  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antibodies, Monoclonal, Murine-Derived--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Asia<br/>Bortezomib--administration & dosage<br/>Cyclophosphamide--administration & dosage<br/>Disease Progression<br/>Doxorubicin--administration & dosage<br/>Europe<br/>Female<br/>Humans<br/>Lymphoma, Mantle-Cell--drug therapy<br/>Male<br/>Middle Aged<br/>Neoplasm Staging<br/>North America<br/>Prednisone--administration & dosage<br/>Progression-Free Survival<br/>Rituximab--administration & dosage<br/>Time Factors<br/>Vincristine--administration & dosage